Found: 20
Select item for more details and to access through your institution.
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 6, p. 1, doi. 10.1093/ofid/ofad225
- By:
- Publication type:
- Article
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 7, p. 1, doi. 10.1093/ofid/ofab320
- By:
- Publication type:
- Article
Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study.
- Published in:
- Open Forum Infectious Diseases, 2018, v. 5, n. 10, p. N.PAG, doi. 10.1093/ofid/ofy241
- By:
- Publication type:
- Article
Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations against Community-Acquired Methicillin-Resistant.
- Published in:
- Drugs in R&D, 2007, v. 8, n. 2, p. 69, doi. 10.2165/00126839-200708020-00001
- By:
- Publication type:
- Article
Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States.
- Published in:
- Antibiotics (2079-6382), 2022, v. 11, n. 5, p. 660, doi. 10.3390/antibiotics11050660
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2024, v. 43, n. 7, p. 1343, doi. 10.1007/s10096-024-04756-4
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2023, v. 42, n. 3, p. 365, doi. 10.1007/s10096-023-04549-1
- By:
- Publication type:
- Article
Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
- Published in:
- American Journal of Health-System Pharmacy, 2006, v. 63, n. 8, p. 750, doi. 10.2146/ajhp050323
- By:
- Publication type:
- Article
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
- Published in:
- Brazilian Journal of Infectious Diseases, 2023, v. 27, n. 3, p. 1, doi. 10.1016/j.bjid.2023.102775
- By:
- Publication type:
- Article
Performance of a vancomycin dosage regimen developed for obese patients.
- Published in:
- American Journal of Health-System Pharmacy, 2012, v. 69, n. 11, p. 944, doi. 10.2146/ajhp110324
- By:
- Publication type:
- Article
Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles: Impact on the Development of Resistance.
- Published in:
- Drugs, 2006, v. 66, n. 1, p. 1, doi. 10.2165/00003495-200666010-00001
- By:
- Publication type:
- Article
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020.
- Published in:
- BMC Microbiology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12866-023-02864-3
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)--SMART 2017-21.
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 4, p. 1, doi. 10.1093/jacamr/dlad098
- By:
- Publication type:
- Article
Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam--SMART 2016-21.
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 3, p. 1, doi. 10.1093/jacamr/dlad080
- By:
- Publication type:
- Article
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 2, p. 1, doi. 10.1093/jacamr/dlad011
- By:
- Publication type:
- Article
In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 1, p. 1, doi. 10.1093/jacamr/dlad003
- By:
- Publication type:
- Article
Pharmacodynamic Target Attainment of Six β-Lactams and Two Fluoroquinolones Against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella Species Collected from United States Intensive Care Units in 2004.
- Published in:
- Pharmacotherapy, 2007, v. 27, n. 3, p. 333, doi. 10.1592/phco.27.3.333
- By:
- Publication type:
- Article
The use of antibiotic pharmacodynamic end points in incremental cost-effectiveness analyses.
- Published in:
- Formulary, 2007, v. 42, n. 4, p. 252
- By:
- Publication type:
- Article
Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms.
- Published in:
- Therapeutic Advances in Infectious Disease, 2021, v. 8, p. 1, doi. 10.1177/20499361211011373
- By:
- Publication type:
- Article
Response to Surawicz et al.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2014, v. 109, n. 10, p. 1684, doi. 10.1038/ajg.2014.224
- By:
- Publication type:
- Article